ag-1549 has been researched along with efavirenz in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, X; Kollman, PA; Kuntz, ID; Wang, J | 1 |
| Chen, J; Chen, X; Geleziunas, R; Hesselgesser, J; Jin, H; Jones, GS; Kim, CU; Tsiang, M; Wright, M; Yu, F; Zeynalzadegan, A | 1 |
| Allan, G; Barba, O; Burt, C; Corbau, R; Dupont, T; Irving, S; Jones, LH; Knöchel, T; Middleton, DS; Mowbray, CE; Perros, M; Phillips, C; Ringrose, H; Swain, NA; Webster, R; Westby, M | 1 |
| Burt, C; Corbau, R; Mowbray, CE; Perros, M; Stupple, PA; Tran, I; Webster, R; Wood, A | 1 |
| Burt, C; Corbau, R; Gayton, S; Hawes, M; Mowbray, CE; Perros, M; Price, DA; Quinton, FJ; Selby, MD; Stupple, PA; Tran, I; Webster, R; Wood, A | 1 |
6 other study(ies) available for ag-1549 and efavirenz
| Article | Year |
|---|---|
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
Topics: Allosteric Site; Anti-HIV Agents; Crystallography, X-Ray; Databases, Factual; Drug Design; HIV Reverse Transcriptase; Models, Molecular; Molecular Conformation; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Statistics as Topic; Thermodynamics | 2005 |
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
Topics: Anti-HIV Agents; Catalytic Domain; CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Synergism; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Molecular Structure; Mutation; Protein Structure, Tertiary; Recombinant Proteins; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; T-Lymphocytes | 2009 |
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Crystallography, X-Ray; Cyclopropanes; Drug Design; Drug Resistance, Viral; Drug Stability; HIV; HIV Reverse Transcriptase; Humans; Imidazoles; Indazoles; Molecular Structure; Mutation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfur Compounds | 2009 |
Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
Topics: Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; Humans; Microsomes, Liver; Pyrazoles; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2009 |
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Reverse Transcriptase; Humans; Microsomes, Liver; Nitriles; Pyrazoles; Rats; Reverse Transcriptase Inhibitors | 2009 |
New drugs in development.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Imidazoles; Kidney Diseases; Lopinavir; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1998 |